ALPHA 0802
Alternative Names: ALPHA-0802Latest Information Update: 15 Feb 2024
Price :
$50 *
At a glance
- Originator AlphaCognition
- Class Granulins; Neuroprotectants
- Mechanism of Action Growth stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Neurodegenerative disorders
Most Recent Events
- 15 Feb 2024 ALPHA 0802 is available for licensing as of 12 Feb 2024. https://www.alphacognition.com/contact/
- 13 Jun 2022 Positive pharmacodynamics data from preclinical studies in Neurodegenerative disorders released by Alpha Cognition
- 12 Jun 2022 Preclinical trials in Neurodegenerative disorders in Canada (Parenteral), before June 2022